Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: January 24, 2003
Last updated: July 23, 2008
Last verified: January 2005

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing head and neck cancer in patients who have oral leukoplakia or head and neck dysplasia.

PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have oral leukoplakia and/or head and neck dysplasia.

Condition Intervention Phase
Head and Neck Cancer
Drug: celecoxib
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Prevention
Official Title: Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: June 2002
Detailed Description:


  • Determine the response rate, in terms of prostaglandin E2 expression, in patients with oral leukoplakia and/or dysplasia treated with celecoxib.
  • Determine the change in other biomarkers including COX-2, Ak+, Ki-67, BCL2, BAX, VEGF, and CD31, in patients treated with this drug.
  • Determine the efficacy of this drug, in terms of reducing the size of oral leukoplakia lesions and presence of dysplasia, in these patients.
  • Correlate change in biomarker expression with response of oral leukoplakia lesions and/or dysplasia in patients treated with this drug.
  • Determine the toxic effects of this drug in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral celecoxib twice daily for 3 months. After 3 months, patients undergo a repeat biopsy. Patients with a positive response receive celecoxib for an additional 9 months.

Patients are followed every 3-6 months for 1 year.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 30 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Oral leukoplakia on clinical examination AND/OR
  • More than one prior squamous cell carcinoma (SCC) of the head and neck and dysplasia on biopsy within the past 6 months
  • Carcinoma in situ or new leukoplakia eligible provided treatment for a prior carcinoma was completed more than 9 months ago



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 months


  • Platelet count at least 100,000/mm^3
  • Absolute neutrophil count greater than 1,500/mm^3
  • No bleeding diathesis


  • Bilirubin less than 1.5 times upper limit of normal (ULN)
  • Transaminases less than 1.5 times ULN
  • PT/PTT less than 1.5 times ULN
  • No acute or chronic liver disease


  • Creatinine less than 1.5 times ULN
  • Urine protein less than 2+
  • No acute or chronic renal insufficiency


  • No New York Heart Association class II congestive heart failure
  • No prior myocardial infarction
  • No angina
  • No known coronary artery disease


  • No advanced chronic obstructive pulmonary disease requiring home oxygen use


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No infection within the past 2 weeks
  • No concurrent infection
  • No concurrent tobacco use (e.g., cigarette, cigar, pipe, or chewing tobacco)

    • At least 1 month since prior use
  • No active alcohol abuse
  • No history of gastrointestinal ulcer
  • No history of anaphylactoid reaction to aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors
  • No concurrent active malignancy except non-melanoma skin cancer
  • No contraindication to nasopharyngoscopy and biopsy


Biologic therapy

  • No concurrent biologic therapy


  • No concurrent chemotherapy

Endocrine therapy

  • More than 3 months since prior absorbed steroids, including inhaled and nasal steroids (3 times a week for at least 2 consecutive weeks)

    • Prior mometasone allowed


  • No concurrent radiotherapy


  • Prior surgery for SCC of the head and neck allowed provided patient has been cancer free for at least 9 months


  • More than 3 months since prior full-dose aspirin, COX-2 inhibitors, or NSAIDs (at least 3 times a week for at least 2 weeks)
  • More than 3 months since prior retinoids or selenium
  • No concurrent lithium or fluconazole
  • No concurrent diuretics for congestive heart failure
  • No concurrent angiotensin-converting enzyme inhibitors
  • Concurrent aspirin allowed if dosage no greater than 81 mg per day
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00052611

United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Study Chair: Lori J. Wirth, MD Dana-Farber Cancer Institute
  More Information Identifier: NCT00052611     History of Changes
Other Study ID Numbers: CDR0000258562
Study First Received: January 24, 2003
Last Updated: July 23, 2008

Keywords provided by National Cancer Institute (NCI):
lip and oral cavity cancer
paranasal sinus and nasal cavity cancer
hypopharyngeal cancer
laryngeal cancer
oropharyngeal cancer
nasopharyngeal cancer
salivary gland cancer

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on April 24, 2017